Cargando…

Clinical outcomes of KRAS-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study

BACKGROUND: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation seemingly suffered less effective therapeutic regimens in the absence of widely-accepted targeted drugs compared with other mutation types in non-small cell lung cancer (NSCLC). However, whether these non-selective therapy schedu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ming-Ming, Zhang, Yong, Wu, Shuo, Zhang, Si-Yuan, Shan, Hui-Liang, Yang, Xue-Min, Xu, Xi, Song, Li-Qiang, Qu, Shuo-Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654440/ https://www.ncbi.nlm.nih.gov/pubmed/38025817 http://dx.doi.org/10.21037/tlcr-23-449

Ejemplares similares

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
por: Chen, Hanxiao, et al.
Publicado: (2022)

Targeting the untargetable KRAS in cancer therapy
por: Liu, Pingyu, et al.
Publicado: (2019)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
por: Liu, Yanxia, et al.
Publicado: (2022)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
por: Kerr, Emma, et al.
Publicado: (2016)

Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine
por: Kapuy, Orsolya, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
por: Al Zubaidi, Tara, et al.
Publicado: (2021)

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
por: Bhattacharya, Saveri, et al.
Publicado: (2015)

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
por: Wang, Haiyun, et al.
Publicado: (2019)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
por: Diehl, J. Nathaniel, et al.
Publicado: (2021)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
por: Liu, Ke, et al.
Publicado: (2018)

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
por: Karimi, Nastaran, et al.
Publicado: (2023)

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells
por: Wang, Kang, et al.
Publicado: (2019)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS
por: Zhang, Zheying, et al.
Publicado: (2018)

Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study
por: Zhou, Xiaoying, et al.
Publicado: (2021)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Simulated-to-real benchmarking of acquisition methods in untargeted metabolomics
por: Wandy, Joe, et al.
Publicado: (2023)

Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
por: Deng, Haoyu, et al.
Publicado: (2019)

Differences in Glycerolipid Response of Chlamydomonas reinhardtii Starchless Mutant to High Light and Nitrogen Deprivation Stress Under Three Carbon Supply Regimes
por: Yang, Miao, et al.
Publicado: (2022)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
por: Wang, Yadong, et al.
Publicado: (2022)

Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling
por: Luo, Yuan-Deng, et al.
Publicado: (2022)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients’ persistence
por: Volkmann, Ingo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uks0k676vba3m334oi8kego69t